Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 116 от 154

Активно (без набиране)

RESPONDER-HF Trial

Heart Failure Heart Failure, Diastolic

Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization

Начало: 17.11.2022 Край: 01.03.2031 Възраст: от 40 г. Лечение

Australia, Belgium, Canada +3 Corvia Medical NCT05425459

Активно (без набиране) Фаза 1/2

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Atypical Teratoid/Rhabdoid Tumor Epithelioid Sarcoma Kidney Medullary Carcinoma Malignant Solid Neoplasm +14

This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immunotherapy with monoclonal antibodies, such as tiragolumab and atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Начало: 17.11.2022 Край: 31.03.2030 Възраст: от 12 г. Лечение

Australia, Canada, United States National Cancer Institute (NCI) NCT05286801

Активно (без набиране)

Vincristine Pharmacokinetics in Infants

Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm

This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children. Vincristine is an anticancer drug used to a variety of childhood cancers. The doses anticancer drugs in children must be adjusted based on the size of the child because children vary significantly in size (height, weight, and BSA) and ability to metabolize drugs from infancy to adolescence. The dose of most anticancer drugs is adjusted to BSA, which is calculated from a patient's weight and height. However, infants and young children have more severe side effects if the BSA is used to calculate their dose, so new dosing models have to be made to safely give anticancer drugs to the youngest patients. This new method uses a BSA-banded approach to determine the dose. Collecting blood samples before and after a dose of the drug will help researchers determine whether this new vincristine dosing method results in equivalent drug levels in the blood over time in infants and young children compared to older children.

Начало: 16.11.2022 Край: 30.09.2026 Възраст: до 12 г.

Australia, Canada, United States Children's Oncology Group NCT05359237

Активно (без набиране) Фаза 1/2

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Urothelial Carcinoma

This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.

Начало: 16.11.2022 Край: 20.06.2028 Възраст: от 18 г. Лечение

Australia, Canada, Chile +8 Merck Sharp & Dohme LLC NCT05562830

Активно (без набиране) Фаза 2

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Becker Muscular Dystrophy

A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker. CANYON and GRAND CANYON are fully enrolled.

Начало: 10.11.2022 Край: 01.09.2026 Възраст: 12–50 г. Лечение

Australia, Belgium, Denmark +8 Edgewise Therapeutics, Inc. NCT05291091

Активно (без набиране) Фаза 3

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Cystic Fibrosis

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.

Начало: 08.11.2022 Край: 30.10.2026 Възраст: от 12 г. Лечение

Australia, Belgium, Canada +16 Vertex Pharmaceuticals Incorporated NCT05444257

Активно (без набиране) Фаза 2

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer

Breast Cancer

This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast cancer, and associated health problems. Olaparib is a type of drug called a PARP (poly \[adenosine diphosphate-ribose\] polymerase) inhibitor. PARP inhibitors can destroy cancer cells that are not good at repairing DNA damage. Olaparib is also approved by US Food and Drug Administration (FDA), European Medicines Agency (EMA) and in other countries for treating women with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Durvalumab is a type of anticancer drug called immunotherapy that targets cancer cells by blocking the signal that prevents the immune system from seeing the cancer cell. Your immune system can then attack and kill the cancer cells. Durvalumab is approved by the FDA and the EMA for the treatment of patients with locally advanced non-small cell lung cancer after receiving chemoradiation therapy and extensive-stage small cell lung cancer in combination with chemotherapy. Some parts of this study are experimental, which means that durvalumab and the combination of olaparib and durvalumab are still in the development stage for the treatment of breast cancer, and they are not approved for treatment of breast cancer, except for use in research studies like this.

Начало: 07.11.2022 Край: 31.12.2026 Възраст: 18–130 г. Лечение

Australia, Belgium, Germany +5 AstraZeneca NCT05498155

Активно (без набиране) Фаза 3

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Thyroid Eye Disease

This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.

Начало: 06.11.2022 Край: 01.08.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Georgia +11 Immunovant Sciences GmbH NCT05517447

Активно (без набиране) Фаза 2

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

Head and Neck Cancer

A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.

Начало: 03.11.2022 Край: 01.08.2026 Възраст: от 18 г. Лечение

Australia, United Kingdom QBiotics Group Limited NCT05608876

Активно (без набиране) Фаза 3

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Obesity

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms. Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.

Начало: 01.11.2022 Край: 19.10.2026 Лечение

Argentina, Australia, Belgium +19 Novo Nordisk A/S NCT05567796

Активно (без набиране) Фаза 3

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.

Начало: 01.11.2022 Край: 19.06.2030 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +16 Hoffmann-La Roche NCT05170204

Активно (без набиране) Фаза 3

Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial

Surgical Site Infection Dementia Cognition

Prophylactic TxA administration in patients undergoing major gastrointestinal surgery reduces the incidence of delirium after surgery when compared with placebo. The unifying hypothesis is that systemic and neuro-inflammation lead to neuronal injury and resultant postoperative delirium.

Начало: 01.11.2022 Край: 31.08.2026 Възраст: 18–100 г. Превенция

Australia Bayside Health NCT05470816

Активно (без набиране) Фаза 1/2

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

Phenylketonuria

The goal of Parts A and B of this Phase 1/2, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differences in bioavailability between a tablet and suspension formulation of JNT-517 and the food effect in healthy volunteers. All participants in Part C will receive JNT-517. The goal of Part D is to assess the safety, tolerability, PK, and effect on urinary Phe and other amino acids of JNT-517 in participants with phenylketonuria (PKU). Participants in Part D will receive either JNT-517 or placebo and will be blinded to their treatment assignment. The study consists of 6 parts: * Part A: SAD in healthy participants -randomized, double-blind, placebo-controlled * Part B: MAD in healthy participants (14 days)-randomized, double-blind, placebo-controlled * Part C: Relative bioavailability of 2 formulations and food effect in healthy participants-randomized, open-label * Part D: Phase 2 in participants with PKU (4 weeks)-randomized, double-blind, placebo-controlled * Part E: Phase 2 in participants with PKU (4 weeks) open label * Part F: SAD Phase 1 in healthy participants, randomized, double-blind, placebo-controlled In each part, participants will complete a Screening Period, a Treatment Period, and a Follow-up Period for safety.

Начало: 31.10.2022 Край: 15.12.2025 Възраст: 18–65 г. Лечение

Australia, United States Otsuka Pharmaceutical Development & Commercialization, NCT05781399

Активно (без набиране) Фаза 3

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

Fabry Disease

An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)

Начало: 31.10.2022 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, Japan, Portugal +3 Amicus Therapeutics NCT04020055

Активно (без набиране)

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

Venous Thromboses Venous Disease Venous Leg Ulcer Venous Stasis +6

This study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for treatment of symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruction in adult patients.

Начало: 25.10.2022 Край: 01.05.2030 Възраст: от 18 г. Лечение

Australia, Germany, Ireland +4 W.L.Gore & Associates NCT05409976

Активно (без набиране) Фаза 3

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Hereditary Angioedema

This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.

Начало: 24.10.2022 Край: 30.06.2026 Възраст: от 12 г. Лечение

Australia, Bulgaria, Canada +18 KalVista Pharmaceuticals, Ltd. NCT05505916

Активно (без набиране) Фаза 3

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Hereditary Angioedema

This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.

Начало: 24.10.2022 Край: 30.06.2026 Възраст: 12–17 г. Лечение

Australia, Bulgaria, Canada +13 KalVista Pharmaceuticals, Ltd. NCT05511922

Активно (без набиране) Фаза 1

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Etentamig co-administered with Pd, Rd, or Dd, will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. This study will include a dose escalation phase to determine the best dose of etentamig, followed by a dose expansion phase to confirm the dose. Approximately 320 adult participants with R/R MM will be enrolled in the study in approximately 48 sites worldwide. Participants will receive intravenous (IV) etentamig co-administered with oral/IV Pd, oral/IV Rd, or oral/IV/subcutaneous (SC) Dd in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Начало: 20.10.2022 Край: 01.09.2033 Възраст: от 18 г. Лечение

Australia, Germany, Italy +4 AbbVie NCT05259839

Активно (без набиране) Фаза 3

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to

Atopic Dermatitis Eczema

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \

Начало: 18.10.2022 Край: 01.12.2026 Възраст: 6–17 г. Лечение

Argentina, Australia, Brazil +9 Eli Lilly and Company NCT05559359

Активно (без набиране) Фаза 1/2

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

Начало: 17.10.2022 Край: 26.02.2027 Възраст: от 18 г. Лечение

Australia, Belgium, France +5 Hoffmann-La Roche NCT05535244

1 … 114 115 116 117 118 … 154